Reports on drug treatments for selective decontamination of the gastrointestinal tract are also failing to pay enough attention to the hazards of therapies, researchers said.
Researchers backed by the US Agency for Healthcare Research and Quality (AHRQ) examined the reporting of 192 randomized drug trials involving more than 130,000 patients in total.
The trials involved seven kinds of treatment, including H. pylori eradication and GI tract decontamination. They also included NSAID trials, HIV therapy and hypertension therapy.
|Medication side effects were adequately explained in just 39% of the 192 drug trials.|
The researchers claimed side effects of medication were adequately explained in just 39% of cases and drug toxicity issues in 29% of reports.
75% quoted the number of patients withdrawn because of drug toxicity - but details were only given in 46% of reports, according to researchers Dr John Ioannidis, of the University of Ioannina, Greece, and Dr Joseph Lau, of The New England Medical Center, Boston, Massachusetts, USA.
Dr John Eisenberg, director of the AHRQ, said, "Adequate reporting of drug safety problems is critical because clinical trials have traditionally been the foundation of high-quality, evidence-based medical practice."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com